Home › Acute Biphenotypic Leukemia › California › Mountain View
Acute Biphenotypic Leukemia clinical trials in Mountain View, CA
4 studies for Acute Biphenotypic Leukemia are looking for participants at sites in and around Mountain View (within about 30 miles). Open a study to see who can join and how to contact the study team.
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Lucile Packard Children's Hospital Stanford University, Palo Alto · 5 mi away
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Lucile Packard Children's Hospital Stanford University, Palo Alto · 5 mi away
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RecruitingPhase 1
- Stanford Health Care, Stanford · 5 mi away
Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
RecruitingPhase 1
- Stanford University, Palo Alto · 5 mi away
Acute Biphenotypic Leukemia trials in other cities
- Seattle, WA15 studies
- Houston, TX11 studies
- New York City, NY10 studies
- Atlanta, GA8 studies
- Durham, NC8 studies
- Chicago, IL7 studies
- Memphis, TN7 studies
- Baldwin Park, CA6 studies
- Los Angeles, CA6 studies
- Charlotte, NC6 studies
- Philadelphia, PA6 studies
- Portland, OR6 studies
Other studies in Mountain View
- Cancer (all types)41 studies
- Metastatic Cancer25 studies
- Breast Cancer24 studies
- Non-Small Cell Lung Cancer22 studies
- Acute Myeloid Leukemia19 studies
- Ovarian Cancer19 studies
- Lung Cancer17 studies
- Autism Spectrum Disorder17 studies
- Prostate Cancer15 studies
- Heart Failure14 studies
- Colorectal Cancer14 studies
- Acute Lymphoblastic Leukemia13 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.